| --- | --- | --- | --- | --- | --- | --- | --- | |-------|-------|----------------------------|-------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Transforming Gene Therapy | | | | | | Agenda & Participants Agenda • Corporate update • Progress advancing lead gene therapy candidate ADVM-022: o Data and enrollment highlights from OPTIC Phase 1 Clinical Trial of ADVM-022 in wet AMD o New INFINITY Phase 2 Clinical Trial of ADVM-022 in Diabetic Macular Edema • Q& ...